Kardigan's stock soared 5.44% during intraday trading on Thursday, marking a strong debut for the clinical-stage biotech company.
The surge follows the company's successful upsized initial public offering, which raised $400 million by selling 25 million shares at $16 each, the top end of its marketed price range. The IPO reflects renewed investor enthusiasm for biotech offerings this year.
Kardigan is developing precision therapeutics for cardiovascular diseases, with three late-stage experimental therapies in its pipeline. The company plans to use the IPO proceeds to fund clinical development of these drugs and for general corporate purposes.